

Cover Story
																				By Matthew Bin Han Ong
In his first talk to  NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute's agenda and research portfolio.
In Brief


Drugs & Targets
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
 ctMoniTR project aims to improve efficiency in development of intermediate endpoints
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
 
            













